TMO — Thermo Fisher Scientific (Stock)

Price: $699.44 · 1 day: -2.55% · 5 days: +3.32% · 1 month: +5.49% · YTD: +20.71%
As of 2026-11-12 21:00 UTC.

52-week range: $435.27 – $727.56 (currently at 90% of the range).

The brief

TMO is in an uptrend, momentum soft. $700 is the level overhead; $668.98 the first support below.

4 of 6 technical checks lean bullish.

TrendUptrend · above 50-day & 200-day
MomentumRSI 53.5 · MACD bearish
Trend strengthADX 18.9 · weak or range
Location+4.5% vs 50-day MA
52-week range-3% from high · +60% from low
VolatilityATR 21.48 · ~3.1%/day

Key levels

LevelTypeDistance
$700.0 (resistance)round0.08%
$721.63 (resistance)52w high3.17%
$750.0 (resistance)round7.23%
$668.98 (support)sma 50-4.35%
$650.0 (support)round-7.07%
$645.49 (support)swing zone-7.71%

Indicators

RSI (14)53.45MACD11.7412
ADX (14)18.9ATR (14)21.48
50-day average$668.98200-day average$554.83

Next earnings: 2027-01-28. TMO earnings date, time and past reactions.

Thermo Fisher Scientific (TMO) stock analysis, November 3, 2026: Uptrend intact as shares press against $700 resistance

Report of 2026-11-03.

Thermo Fisher Scientific (TMO) filed third-quarter results showing revenue up 9% to $12.14 billion, and the stock now trades at $698.39. That is 1.5% below its October 29 peak and just under $700 resistance. The weekly uptrend is intact, and the balance of evidence leans positive with medium conviction. A clean breakout is a harder case: volume is light, and the math from $700 is poor.

Why it matters

The quarter was solid and unsurprising. According to the 10-Q filing, revenue rose 9% from a year earlier and net income grew 6% to $1.72 billion. The shares set their high close of $709.18 on October 29, the day before the filing, and sit 1.5% below it. The market had already paid for a good quarter, and the numbers confirmed the story rather than changing it. The same day, Investing.com reported that executive vice president Michael Shafer will retire effective December 31, 2026. No successor or details were given, and the stock has not reacted to it.

The last five days show how much of the move belongs to the stock. TMO gained 0.8% while the S&P 500 (SPY) fell 2.1% and the healthcare sector ETF (XLV) rose 2.8%. The stock held up in a falling market but trailed its own sector by 2.1 points. Today's 2.3% jump comes with SPY up just 0.2% and XLV down 0.2%. Nothing in the news dated today explains it, so it looks like buying in the stock itself rather than a response to an event.

The argument about TMO is about the cycle, not the company. Morningstar takes the positive side: TMO is handling the downturn in biopharma spending and softness in China better than most peers, and its broad portfolio and manufacturing capability have helped it hold and grow customer wallet share. The same note concedes the exposure to a weak life science market. That caveat is the cautious side of the debate, and none of the sources reviewed makes an outright negative case. On the price-target side, Stifel raised its target from $650 to $775 with a Buy rating when the shares were at $694.02.

Valuation leaves less room than the headline rating suggests. All 25 analysts together rate the stock a strong buy, and the mean price target of $752.12 sits 7.1% above the price. The spread is wide, though, from $590 to $830. The stock has gained 48.8% in six months and 20.5% this year, against 10.5% for the S&P 500, so much of the optimism is already in the price.

What the evidence says

The long-term thesis is intact. Price is above its 40-week average, the 50-day average at $657.11 sits well above the 200-day at $552.06, and the stock is 59.33% above its 52-week low of $438.34. Over 50 days it leads the S&P 500 by 8.1%, and over 200 days by 22.5%. This is a mature advance that has stalled just under its high rather than a young trend. A relative strength index of 58.24 shows it is not stretched.

For the next 2 to 6 weeks the balance of evidence leans positive, with medium conviction: two of four points. The daily trend runs with the weekly uptrend, and the stock is leading the market. Conviction is held down because the stock trails XLV by 0.5% over 50 days, which runs against the trend, and because the breakout math below is weak.

The strongest case against the positive reading is that the sector is doing the work and TMO is not. XLV is up 10.9% over a month against 6.7% for TMO, and the five-day gap is 2.1 points. Volume is also running 60.2% below its 20-day average at the time of writing, so the push toward $700 has little behind it. This is why conviction is not higher. It does not tip the balance, because the price still sits above every trend marker and the 50-day average is far below.

Levels that matter

The structure holds above $657.11, the 50-day average, and the first crack would come on a close below it. Beneath sit $650 and then the swing zone at $645.49, where the trend ends. Below that the next support is $631.7, then $600. These levels matter because they are where earlier buyers stepped in, and the 50-day average has guided the advance.

The breakout level is a daily close above $700 on volume above its 20-day average. The first target is the $709.18 52-week high, and a breakout would be wrong below $651.62, which is the 50-day average minus a quarter of the 14-day average true range. That gives a reward-to-risk of 0.2 to 1. The math does not reach 3 to 1 against any target on the map. Even the $750 round number falls well short, and it would take a target beyond the highest analyst figure of $830, or a much tighter stop, to get there.

What would change the picture

A weekly close below $645.49 would change the picture, because it would break the swing zone that defines the end of the trend. The non-price fact that would do it is evidence that the life science spending downturn is deepening, such as weaker guidance or worsening demand in China. That is the exposure Morningstar flags, and it would undercut the idea that TMO is handling the cycle better than peers.

What to watch

Latest TMO news

Explore more

Interactive TMO chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs